ProfileGDS5678 / 1415850_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 83% 82% 85% 86% 78% 82% 86% 83% 83% 83% 84% 83% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.9361782
GSM967853U87-EV human glioblastoma xenograft - Control 26.1234883
GSM967854U87-EV human glioblastoma xenograft - Control 35.9067682
GSM967855U87-EV human glioblastoma xenograft - Control 46.482385
GSM967856U87-EV human glioblastoma xenograft - Control 56.5094786
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.1778178
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.8124482
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.4475186
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.0402483
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.0920583
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.0739283
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.2219684
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.0496183
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.8937882